The FDA approved donanemab for full approval in July 2024 after the TRAILBLAZER-ALZ 2 trial (NCT04437511) showed it reduced integrated Alzheimer’s Disease Rating Scale (iADRS) by 35% in patients with early AD (MMSE 20–28) with low/medium tau levels during 18 months with 80% plaque clearance at 10 mg/kg IV every four weeks [15]. Here, MAPT is linked to Alzheimer disease.